Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-24-005799
Filing Date
2024-08-16
Accepted
2024-08-15 20:19:25
Documents
60
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR JUNE 2024 coeptis_i10q-063024.htm   iXBRL 10-Q 1105661
2 CERTIFICATION coeptis_ex3101.htm EX-31.1 8523
3 CERTIFICATION coeptis_ex3102.htm EX-31.2 8446
4 CERTIFICATION coeptis_ex3201.htm EX-32.1 2715
5 CERTIFICATION coeptis_ex3202.htm EX-32.2 2776
  Complete submission text file 0001683168-24-005799.txt   6172093

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE coep-20240630.xsd EX-101.SCH 48774
7 XBRL CALCULATION FILE coep-20240630_cal.xml EX-101.CAL 53903
8 XBRL DEFINITION FILE coep-20240630_def.xml EX-101.DEF 215690
9 XBRL LABEL FILE coep-20240630_lab.xml EX-101.LAB 373679
10 XBRL PRESENTATION FILE coep-20240630_pre.xml EX-101.PRE 307949
63 EXTRACTED XBRL INSTANCE DOCUMENT coeptis_i10q-063024_htm.xml XML 839111
Mailing Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090
Business Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090 724-934-6467
Coeptis Therapeutics Holdings, Inc. (Filer) CIK: 0001759186 (see all company filings)

EIN.: 981465952 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39669 | Film No.: 241213920
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)